Including UV1 to Keytruda didn’t enhance survival outcomes in sufferers with head and neck most cancers.
Including the most cancers vaccine, UV1, to Keytruda (pembrolizumab) didn’t lead to medical advantages concerning illness development or survival amongst sufferers with metastatic or recurrent head and neck most cancers.
Within the section 2 FOCUS trial, topline information confirmed that the addition of UV1 to the present commonplace of care of Keytruda as a first-line remedy in sufferers with metastatic most cancers or as a second-line remedy for sufferers with recurrent PD-L1 optimistic head and neck squamous cell carcinoma (HNSCC) didn’t meet the research aim of progression-free survival (the time a affected person lives with out their illness spreading or worsening) at six months, in accordance with a information launch from UV1 producer Ultimovacs.
UV1 additionally didn’t result in an enchancment in total survival, which is outlined because the time a affected person lives no matter illness standing, in accordance with the information launch.
“We’ve got applied a broad section 2 medical growth program testing our most cancers vaccine in a spread of various indications. Sadly, the FOCUS research didn’t present us with the outcomes we had hoped for, and we’re disenchanted that UV1 was not in a position to present added medical profit for these HNSCC sufferers,” said Carlos de Sousa, chief govt officer at Ultimovacs, within the information launch.
Study Extra: ‘Extra is Not All the time Higher’ in Chemoradiotherapy for Head and Neck Most cancers
With roughly 75 sufferers at 10 websites throughout Germany, the FOCUS trial launched in August 2021, in accordance with Ultimovacs and the trial’s itemizing on clinicaltrials.gov. All sufferers had been adopted up with for near 12 months or longer to guage progression-free survival, total survival and security, in accordance with the information launch.
UV1, in accordance with the Nationwide Most cancers Institute, is an artificial peptide vaccine meant to stimulate cytotoxic T cells to acknowledge and kill cells that specific telomerase, an enzyme sometimes repressed in wholesome cells and overexpressed in most most cancers cells, enjoying a vital position in mobile proliferation.
Underneath the present commonplace of care of immune checkpoint blockade remedy with or with out chemotherapy, the median total survival time for sufferers with metastatic or recurrent head and neck squamous cell carcinoma is lower than 15 months, with many sufferers too frail to tolerate chemotherapy, in accordance with the information launch from Ultimovacs.
Study Extra: What to Anticipate With a Excessive Threat of Head and Neck Most cancers Recurrence
UV1 Is at present being investigated for the remedy of ovarian most cancers within the section 2 DOVACC trial, in accordance with the information launch. The trial evaluates Lynparza (olaparib) and Imfinzi (durvalumab) with or with out UV1 versus stand-alone Lynparza as a second-line upkeep remedy for sufferers with high-grade, BRCA-negative ovarian most cancers, with topline outcomes from that trial anticipated to be launched within the first half of 2025, in accordance with Ultimovacs.
“We’re disenchanted that the FOCUS trial didn’t obtain the specified final result for sufferers, which underscores the complexities of treating metastatic and recurrent head and neck most cancers,” mentioned Jens Bjørheim, chief medical officer at Ultimovacs, within the information launch. “This most cancers kind is especially aggressive with restricted remedy choices and excessive charges of recurrence. Our broad medical growth program was designed to determine the very best affected person populations for UV1 and we are actually focusing our efforts on the upcoming DOVACC information readout within the first half of subsequent yr.”
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
